Aisin Corp

Aisin Corp maintains a capital structure with a debt-to-equity ratio of 0.37, indicating a relatively conservative leverage position. The company's liquidity position is characterized by a current ratio of 1.68, suggesting it has sufficient short-term assets to cover its short-term liabilities. However, the company's net cash position is negative after subtracting total debt, signaling potential liquidity constraints. In terms of profitability, Aisin Corp's return on equity (ROE) is 0.0065, and its return on assets (ROA) is 0.003, both of which are below the typical thresholds for strong performance in the automotive parts industry. The company's operating margin, calculated as operating income divided by revenue, is 2.85%, which is in line with the industry median for similar firms. Aisin Corp's revenue is heavily concentrated in the automotive parts segment, with a significant portion of its business tied to Toyota and other major automakers. The company's geographic exposure is primarily within Japan, with limited international diversification, which may increase its vulnerability to regional economic fluctuations. The company's growth trajectory is modest, with a price-to-earnings (P/E) ratio of 124.35, which is significantly higher than the industry median, suggesting that the market may be pricing in low near-term earnings growth. Analysts have provided a mean price target of 2,937.14 JPY, indicating a potential upside from the current market price of 2,348 JPY. Aisin Corp faces several risk factors, including liquidity constraints and the potential for dilution, although the latter is currently assessed as low. The company's capital expenditures are substantial, with a negative value of -55,393 million JPY, indicating significant investment in long-term assets. The company's risk assessment highlights the need for continued monitoring of its liquidity position and capital structure. Recent events and filings have not indicated any major changes in the company's strategic direction or financial health. The company's recent financial performance and analyst estimates suggest a cautious outlook, with a mean recommendation of 2.47, which is closer to a "hold" than a "buy".